TOP > 外国特許検索 > USE OF PEPTIDYL-PROLYL ISOMERASE PIN1 FOR CONTROLLING STABLE MAINTENANCE AND RENEWAL OF STEM CELLS

USE OF PEPTIDYL-PROLYL ISOMERASE PIN1 FOR CONTROLLING STABLE MAINTENANCE AND RENEWAL OF STEM CELLS

外国特許コード F120006562
整理番号 S2010-1143
掲載日 2012年5月10日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP074384
国際公開番号 WO 2012057052
国際出願日 平成23年10月24日(2011.10.24)
国際公開日 平成24年5月3日(2012.5.3)
優先権データ
  • 特願2010-238548 (2010.10.25) JP
発明の名称 (英語) USE OF PEPTIDYL-PROLYL ISOMERASE PIN1 FOR CONTROLLING STABLE MAINTENANCE AND RENEWAL OF STEM CELLS
発明の概要(英語) Provided is a technique which enables highly efficient and stable establishment, maintenance and renewal of induced pluripotent stem (iPS) cells. A method for producing induced pluripotent stem cells from somatic cells, which comprises a step for enhancing the expression of peptidyl-prolyl isomerase Pin1 in somatic cells. Induced pluripotent stem cells which are produced by the above-described method. An agent for enhancing somatic cell reprogramming, a medical agent for activating the self-renewal of induced pluripotent stem cells and a medical agent for maintaining the pluripotency of induced pluripotent stem cells, each of which contains a substance that enhances the expression of peptidyl-prolyl isomerase Pin1 in somatic cells and/or peptidyl-prolyl isomerase Pin1. A medical agent for inhibiting the self-renewal of induced pluripotent stem cells, a medical agent for impairing the pluripotency of induced pluripotent stem cells and a medical agent for killing induced pluripotent stem cells and/or cancer stem cells, each of which contains a substance that inhibits peptidyl-prolyl isomerase Pin1. An Oct-4 protein stabilizer and an agent for enhancing the transcriptional activity of Oct-4 protein, each of which contains peptidyl-prolyl isomerase Pin1 and/or a Pin1 gene.
従来技術、競合技術の概要(英語) BACKGROUND ART
In recent years, regenerative medicine using stem cells is expected, researches and development for the practical use are implemented throughout the world. Pluripotent stem cells using techniques include, embryonic stem cells (ES) using regenerative medicine has been made about the study, serving as the origin of life ES embryonic cells are separated from the cells and therefore, on its clinical use, ethical problem arises. Yamanaka et al. recently, two transcriptional factors 4 (Oct3/4, Sox2, Klf-4, c-Myc) by transduction of fibroblasts to induced pluripotent stem (iPS) cells and direct reprogramming (non-patent document 1) has succeeded. However, in the current methods creating stem cells (iPS cells) has low stability, the efficiency of the de-differentiation in question is very low. Also, such as by retroviral gene transfer method is used, the gene into the genome of a cell introduced at random, as a result, by insertion of a gene such as activation of the endogenous cancer gene with a gene mutation occurs it is possible that the malignant cells have been noted. In order to overcome these problems, maintenance of stem cells and a method to effectively control the growth, cancer cells develop removed efficiently is considered a very important role.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • Public University Corporation Yokohama City University
  • 発明者(英語)
  • RYO, Akihide
  • NISHI, Mayuko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close